Targeting IL-17A for the treatment of pustular psoriasis: a comprehensive review

References

• Genovese G, Moltrasio C, Cassano N, et al. Pustular psoriasis: from pathophysiology to treatment. Biomedicines. 2021;9:1746.
   PubMed Web of Science ®Google Scholar
• Huang Y-W, Tsai T-F. HLA-Cw1 and Psoriasis. Am J Clin Dermatol. 2021;22:339–347.
   PubMed Web of Science ®Google Scholar
• Singh R, Koppu S, Perche PO, et al. The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications. Int J Mol Sci. 2021;22:12793.
   PubMed Web of Science ®Google Scholar
• Menter A, Van Voorhees AS, Hsu S. Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options. Dermatol Ther. 2021;11:1917–1929.
   Web of Science ®Google Scholar
• Gu C, Wu L, Li X. IL-17 family: cytokines, receptors and signaling. Cytokine. 2013;64:477–485.
   PubMed Web of Science ®Google Scholar
• Yilmaz SB, Cicek N, Coskun M, et al. Serum and tissue levels of IL-17 in different clinical subtypes of psoriasis. Arch Dermatol Res. 2012;304:465–469.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol JEADV. 2014;28:1298–1305.
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Fuentes-Duculan J, Mashiko S, et al. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J Dermatol Sci. 2017;85:20–26.
   PubMed Web of Science ®Google Scholar
• Kakeda M, Schlapbach C, Danelon G, et al. Innate immune cells express IL-17A/F in acute generalized exanthematous pustulosis and generalized pustular psoriasis. Arch Dermatol Res. 2014;306:933–938.
   PubMed Web of Science ®Google Scholar
• Falto-Aizpurua LA, Martin-Garcia RF, Carrasquillo OY, et al. Biological therapy for pustular psoriasis: a systematic review. Int J Dermatol. 2020;59:284–296.
   PubMed Web of Science ®Google Scholar
• Wang W-M, Jin H-Z. Biologics in the treatment of pustular psoriasis. Expert Opin Drug Saf. 2020;19:969–980.
   PubMed Web of Science ®Google Scholar
• Krueger J, Puig L, Thaçi D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23:51–64.
   PubMed Web of Science ®Google Scholar
• Kearns DG, Chat VS, Zang PD, et al. Review of treatments for generalized pustular psoriasis. J Dermatol Treat. 2021;32:492–494.
   PubMed Web of Science ®Google Scholar
• Boehner A, Navarini AA, Eyerich K. Generalized pustular psoriasis - a model disease for specific targeted immunotherapy, systematic review. Exp Dermatol. 2018;27:1067–1077.
   PubMed Web of Science ®Google Scholar
• Reich A. Interleukin-17 blockade in generalized pustular psoriasis - new hope for severely ill patients. Br J Dermatol. 2017;176:572–573.
   PubMed Web of Science ®Google Scholar
• Komine M, Morita A. Generalized pustular psoriasis: current management status and unmet medical needs in Japan. Expert Rev Clin Immunol. 2021;17:1015–1027.
   PubMed Web of Science ®Google Scholar
• Kromer C, Loewe E, Schaarschmidt M-L, et al. Drug survival in the treatment of generalized pustular psoriasis: a retrospective multicenter study. Dermatol Ther. 2021;34:e14814.
   PubMed Web of Science ®Google Scholar
• Miyachi H, Konishi T, Kumazawa R, et al. Treatments and outcomes of generalized pustular psoriasis: a cohort of 1516 patients in a nationwide inpatient database in Japan. J Am Acad Dermatol. 2022;86:1266–1274.
   PubMed Web of Science ®Google Scholar
• Smith MP, Ly K, Thibodeaux Q, et al. Acrodermatitis continua of Hallopeau: clinical perspectives. Psoriasis Targets Ther. 2019;9:65–72.
   PubMed Web of Science ®Google Scholar
• Maliyar K, Crowley EL, Rodriguez-Bolanos F, et al. The use of biologic therapy in the treatment of acrodermatitis continua of Hallopeau: a Review. J Cutan Med Surg. 2019;23:428–435.
   PubMed Web of Science ®Google Scholar
• Frieder J, Kivelevitch D, Menter A. Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis. Ther Adv Chronic Dis. 2018;9:5–21.
   PubMed Web of Science ®Google Scholar
• Imafuku S, Honma M, Okubo Y, et al. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: a 52-week analysis from phase III open-label multicenter Japanese study. J Dermatol. 2016;43:1011–1017.
   PubMed Web of Science ®Google Scholar
• Böhner A, Roenneberg S, Eyerich K, et al. Acute generalized pustular psoriasis treated with the IL-17A antibody secukinumab. JAMA Dermatol. 2016;152:482–484.
   PubMed Web of Science ®Google Scholar
• Polesie S, Lidholm AG. Secukinumab in the treatment of generalized pustular psoriasis: a case report. Acta Derm Venereol. 2017;97:124–125.
   PubMed Web of Science ®Google Scholar
• Mugheddu C, Atzori L, Lappi A, et al. Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis. J Eur Acad Dermatol Venereol JEADV. 2017;31:e420–e421.
   PubMed Web of Science ®Google Scholar
• Madanagobalane S. Secukinumab in generalized pustular psoriasis. Indian Dermatol Online J. 2018;9:464–466.
   PubMedGoogle Scholar
• Sun Z-L, Liu Z-L, Y-Y X, et al. Successful treatment of generalized pustular psoriasis with secukinumab: a report of two cases. Chin Med J (Engl). 2020;133:3015–3016.
   PubMed Web of Science ®Google Scholar
• Akaji K, Nakagawa Y, Kakuda K, et al. Generalized pustular psoriasis associated with systemic lupus erythematosus successfully treated with secukinumab. J Dermatol. 2021;48:e43–e44.
   PubMed Web of Science ®Google Scholar
• Wilsmann-Theis D, Schnell LM, Ralser-Isselstein V, et al. Successful treatment with interleukin-17A antagonists of generalized pustular psoriasis in patients without IL36RN mutations. J Dermatol. 2018;45:850–854.
   PubMed Web of Science ®Google Scholar
• Yeung J, Valbuena V. Successful use of secukinumab in pustular psoriasis. JAAD Case Rep. 2016;2:470–472.
   PubMedGoogle Scholar
• Honma M, Nozaki H, Hayashi K, et al. Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab. J Dermatol. 2019;46:e468–e469.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80:1344–1352.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Bachelez H, Burden AD, et al. Efficacy and safety of secukinumab in moderate to severe palmoplantar pustular psoriasis over 148 weeks: extension of the 2PRECISE study. J Am Acad Dermatol. 2021;84:552–554.
   PubMed Web of Science ®Google Scholar
• Reolid A, Armesto S, Sahuquillo-Torralba A, et al. Secukinumab is effective and safe in the treatment of recalcitrant palmoplantar psoriasis and palmoplantar pustular psoriasis in a daily practice setting. J Am Acad Dermatol. 2022 Sep;87(3):705-709.
   PubMed Web of Science ®Google Scholar
• Muggli D, Maul J-T, Anzengruber F, et al. Secukinumab for acrodermatitis continua of Hallopeau. JAMA Dermatol. 2017;153:336–337.
   PubMed Web of Science ®Google Scholar
• S E, M J, Mp S, et al. Two cases of acrodermatitis continua suppurativa (Hallopeau’s disease) treated with IL-17A inhibitors. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG [Internet]. 2019;17. [cited 2022 Jun 6]. Available from: https://pubmed.ncbi.nlm.nih.gov/31241836/
   Google Scholar
• Balestri R, Rech G, Tasin L, et al. Acrodermatitis continua of Hallopeau successfully treated with secukinumab. J Dermatol Treat. 2018;29:3–5.
   PubMed Web of Science ®Google Scholar
• Smirnova LM, Vertieva EY, Olisova OY, et al. Outcomes of various types of therapy in patients with treatment-resistant acrodermatitis continua of Hallopeau. Biol Targets Ther. 2019;13:83–87.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, D’Adamio S, Teoli M, et al. Biologic therapy for acrodermatitis continua of Hallopeau: successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019;32:e12899.
   PubMed Web of Science ®Google Scholar
• Kromer C, Loewe E, Schaarschmidt M-L, et al. Treatment of acrodermatitis continua of Hallopeau: a case series of 39 patients. J Dermatol. 2020;47:989–997.
   PubMed Web of Science ®Google Scholar
• Baron JA. Acrodermatitis of Hallopeau and erosive oral mucositis successfully treated with secukinumab. JAAD Case Rep. 2017;3:215–218.
   PubMedGoogle Scholar
• López-Sánchez C, Falla LM, Roé-Crespo E, et al. Excellent response to secukinumab in an infant with severe generalized pustular psoriasis. J Dermatol. 2021;48:907–910.
   PubMed Web of Science ®Google Scholar
• Albela H, Begum S, Leong KF. Successful treatment of paediatric generalized pustular psoriasis with secukinumab: a case series. J Dermatol Treat. 2022 May;33(3):1769–1773.
   Web of Science ®Google Scholar
• P-H H, Tsai T-F. Successful treatment of refractory juvenile generalized pustular psoriasis with secukinumab monotherapy: a case report and review of published work. J Dermatol. 2018;45:1353–1356.
   PubMed Web of Science ®Google Scholar
• Zhu H, Song P, Du D, et al. Successful treatment of a 3-year-old girl with generalized pustular psoriasis using secukinumab monotherapy. Pediatr Dermatol. 2021;38:1366–1367.
   PubMed Web of Science ®Google Scholar
• Jing G, Bin W, Ying ZZ. Rapid response to secukinumab in a 5-year-old with deficiency of the interleukin-36 receptor antagonist (DITRA) with severe scalp and nail involvement. Pediatr Dermatol. 2021;38:1258–1263.
   PubMed Web of Science ®Google Scholar
• Cordoro KM, Ucmak D, Hitraya-Low M, et al. Response to interleukin (IL)-17 inhibition in an adolescent with severe manifestations of IL-36 receptor antagonist deficiency (DITRA). JAMA Dermatol. 2017;153:106–108.
   PubMed Web of Science ®Google Scholar
• Ruan S-F, Zhang -L-L, Liu Z, et al. Real-world data on the clinical use of secukinumab in pediatric generalized pustular psoriasis: a 48-week retrospective study. J Am Acad Dermatol. 2022 May 16:S0190-9622(22)00806-4.
   Google Scholar
• Shelton SK, Bai SR, Jordan JK, et al. Ixekizumab: a review of its use for the management of moderate to severe plaque psoriasis. Ann Pharmacother. 2019;53:276–284.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Ishii T, et al. Efficacy and safety of open-label ixekizumab treatment in Japanese patients with moderate-to-severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis. J Eur Acad Dermatol Venereol JEADV. 2015;29:1148–1155.
   PubMed Web of Science ®Google Scholar
• Saeki H, Nakagawa H, Nakajo K, et al. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: results from a 52-week, open-label, phase 3 study (UNCOVER-J). J Dermatol. 2017;44:355–362.
   PubMed Web of Science ®Google Scholar
• Okubo Y, Mabuchi T, Iwatsuki K, et al. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J). J Eur Acad Dermatol Venereol JEADV. 2019;33:325–332.
   PubMed Web of Science ®Google Scholar
• Egawa G, Honda T, Kabashima K. Long-term efficacy of ixekizumab in erythrodermic and generalized pustular psoriasis patients. J Eur Acad Dermatol Venereol JEADV. 2019;33:259.
   PubMed Web of Science ®Google Scholar
• Morita A, Okubo Y, Morisaki Y, et al. Ixekizumab 80 mg every 2 weeks treatment beyond week 12 for Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis. Dermatol Ther. 2022;12:481–494.
   PubMed Web of Science ®Google Scholar
• Dattola A, Manfreda V, Esposito M, et al. A case of generalized pustular psoriasis and arthritis treated with ixekizumab. J Dermatol Treat. 2020;31:754–755.
   PubMed Web of Science ®Google Scholar
• Megna M, Abategiovanni L, Annunziata A, et al. Generalized pustular psoriasis rapidly and successfully treated with ixekizumab in a Caucasian patient. Dermatol Ther. 2022;35:e15382.
   PubMed Web of Science ®Google Scholar
• Nagata M, Kamata M, Fukaya S, et al. Real-world single-center experience with 10 cases of generalized pustular psoriasis successfully treated with ixekizumab. J Am Acad Dermatol. 2020;82:758–761.
   PubMed Web of Science ®Google Scholar
• Avallone G, Cariti C, Dapavo P, et al. Real-life comparison between secukinumab and ixekizumab in the treatment of pustular and erythrodermic psoriasis. J Eur Acad Dermatol Venereol JEADV. 2022;36:e574–e576.
   PubMed Web of Science ®Google Scholar
• He F, Long F, Yin Z, et al. Local injection of low-dose ixekizumab for the treatment of palmoplantar pustular psoriasis. Int J Dermatol. 2022;61:742–743.
   PubMed Web of Science ®Google Scholar
• Miller AC, Holland TE, Cohen DJ. Treatment of acrodermatitis continua of hallopeau with ixekizumab. J Dermatol Treat. 2021;32:117–119.
   PubMed Web of Science ®Google Scholar
• Blair HA. Brodalumab: a Review in moderate to severe plaque psoriasis. Drugs. 2018;78:495–504.
   PubMed Web of Science ®Google Scholar
• Yamasaki K, Nakagawa H, Kubo Y, et al. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176:741–751.
   PubMed Web of Science ®Google Scholar
• Pinter A, Wilsmann-Theis D, Peitsch WK, et al. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: report on four cases. J Dermatol. 2019;46:426–430.
   PubMed Web of Science ®Google Scholar
• Nakao M, Asano Y, Kamata M, et al. Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol EJD. 2018;28:538–539.
   PubMed Web of Science ®Google Scholar
• Khemis A, Cavalié M, Montaudié H, et al. Rebound pustular psoriasis after brodalumab discontinuation. Br J Dermatol. 2016;175:1065–1066.
   PubMed Web of Science ®Google Scholar
• Okazaki S, Hoashi T, Saeki H, et al. A case of autoimmune hepatitis/primary biliary cholangitis overlap syndrome during treatment with brodalumab for generalized pustular psoriasis. J Nippon Med Sch Nippon Ika Daigaku Zasshi. 2021; 88: 569–573.
   PubMed Web of Science ®Google Scholar
• Milani-Nejad N, Kaffenberger J. Treatment of recalcitrant acrodermatitis continua of Hallopeau with brodalumab. J Drugs Dermatol JDD. 2019;18:1047.
   PubMed Web of Science ®Google Scholar
• Passante M, Dastoli S, Nisticò SP, et al. Effectiveness of brodalumab in acrodermatitis continua of Hallopeau: a case report. Dermatol Ther. 2020;33:e13170.
   PubMed Web of Science ®Google Scholar
• Bardazzi F, Di Altobrando A, Lacava R. Brodalumab in the treatment of recalcitrant acrodermatitis continua of Hallopeau. Dermatol Ther. 2020;33:e14301.
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Potestio L, Camela E, et al. Bimekizumab for the treatment of psoriasis: a review of the current knowledge. Psoriasis Targets Ther. 2022;12:127–137.
   PubMed Web of Science ®Google Scholar
• Bachelez H, Choon S-E, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385:2431–2440.
   PubMed Web of Science ®Google Scholar